The landscape of obesity treatment is changing dramatically with the emergence of several promising injectable therapies. the GLP-1/GIP dual agonist, Cagrilintide , a GLP-1/GIP/GCG triple agonist , and AOD-9604 https://nexaphresearchpeptides.com/product-category/experimental-blends/